EYPT EyePoint Pharmaceuticals
- 9.190
- +0.190+2.11%
- 9.190
- 0.0000.00%
EyePoint Pharmaceuticals News
Karen Zaderej Spends US$100k Buying EyePoint Pharmaceuticals Shares
Outperform Rating Reaffirmed for EyePoint Pharmaceuticals Amidst Promising Duravyu Developments
Some Analysts Just Cut Their EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Estimates
Express News | JP Morgan Maintains Overweight on EyePoint Pharmaceuticals, Lowers Price Target to $29
J.P. Morgan Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Cuts Target Price to $29
EyePoint Pharmaceuticals Analyst Ratings
Express News | EyePoint Pharmaceuticals Inc : JP Morgan Cuts Target Price to $29 From $32
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported And Analysts Have Been Cutting Their Estimates
Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 37% Discount?
Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (EYPT), Sarepta Therapeutics (SRPT) and Intra-Cellular Therapies (ITCI)
Express News | EyePoint Pharmaceuticals Inc Files for Mixed Shelf of up to $400 Mln – SEC Filing
EyePoint Pharmaceuticals | 10-Q: Q2 2024 Earnings Report
Optimistic 'Buy' Rating for EyePoint Pharmaceuticals Amidst Promising DURAVYU Trial Prospects
EyePoint Pharmaceuticals Earns Buy Rating on Duravyu's Promising Efficacy and Safety Profile
Express News | EyePoint Pharmaceuticals' Cash And Investments Of $280.2M Is Expected To Provide Cash Runway Into 2026
Express News | EyePoint Pharmaceuticals Q2 2024 GAAP EPS $(0.58) Misses $(0.53) Estimate, Sales $9.477M Miss $9.593M Estimate
Express News | EyePoint Pharmaceuticals Inc: Cash Runway Through Phase 3 Wet AMD Topline Data for Duravyu in 2026
Earnings Flash (EYPT) EYEPOINT PHARMACEUTICALS Reports Q2 Revenue $9.5M
Express News | EyePoint Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Developments
Express News | EyePoint Pharmaceuticals Q2 Operating Income USD -34.546 Million
Analysis
Price Target
No Data
